Biotech firms, wanting to go public, have had to seek alternative means of doing so. Reverse mergers represented
one such alternative.
Biotech firm Catalyst Biosciences (Catalyst) had early success in partnering with Pharmaceutical giant, Wyeth,
having reached an agreement to license its drug designed to control bleeding in late 2009. But the results of the
partnership in the ensuing years were modest. Catalyst had drugs in development (in the so-called pipeline) and
other drugs that were at various stages of clinical testing. But the firm needed money and was unable to get
financing from big pharmaceutical firms. By 2015, Catalyst went public in a reverse merger with publicly traded
Targacept, the beleaguered biotech that had suffered a number of clinical trial failures in recent years. Targacept had
little to attract investment from big drug companies and in late 2014 its partnership with AstreZeneca fell apart
diminishing its royalty revenue stream. Targacept was left to search for a new role for itself in the biotech industry.
Targacept still had substantial cash on hand but few attractive investment opportunities. Its prospects were to
continue to burn cash by going it alone, seek a partner, or merge with a firm having significant growth opportunities.
The firm projected that at the current rate of usage it would exhaust its cash on hand in 18 to 24 months and few
parties seemed interested in investing in the foundering company. A merger seemed like the best hope. Targacept
tried to conserve cash by cutting back on its operations. But this would simply extend the day of reckoning. By the
time it was able to find a merger partner, it had laid off most of its employees. By early 2015, Targacept had just 18
full time employees down from a peak of 144 in 2012.
In contrast to Targacept, Catalyst had a series of promising new drugs but was running short of cash. The long–
lead time required to bring drugs to market means that many biotech firms experience an inability to finance
aggressive R&D projects. To finance future research and development, it too had to partner with a large
pharmaceutical firm, or to go public through an IPO or a reverse merger. Cutbacks at large drug companies made
the likelihood of finding an investment partner slim and the lackluster stock market made an IPO impractical.
Therefore, the firm decided it needed to merge with a cash flush public firm which offered the opportunity to attract
new R&D talent with the offer of stock options and the ability to raise cash through future equity issues.
Early in 2015, biotech firm Tobira Therapeutics tested the waters by going public through a reverse merger after
its IPO fizzled. This successful reverse merger seemed to pave the way for Catalyst to pursue this means of going
public during the choppy 2015 stock market. The merger between Catalyst and Targacept was announced in May
2015 and represented the creation of a new company named Catalyst Biosciences. The new firm contained
Catalyst’s protease therapeutics pipeline and financial resources came mostly from Targacept. It represented a well–
funded firm hoping to develop new treatment options for patients with bleeding disorders.
While conventional IPOs can take months to complete, reverse mergers can take only a few weeks. Moreover, as
the reverse merger is solely a mechanism to convert a private company into a public entity, the process is less
dependent on financial market conditions because the company often is not proposing to raise capital at the time it
goes public.
At closing, the combined firms had a pipeline of protease therapeutics, four other promising drug candidates, and
cash and cash equivalents of $40 million. Of the cash on hand, $35 million came from Targacept and the remaining
$5 million came from Catalyst, Existing Targacept shareholders received a special dividend prior to closing of about
$20 million distributed from Targacept’s cash on hand and redeemable convertible notes (convertible into Catalyst
Biosciences common shares) totally $37 million. The notes are guaranteed by the new firm Catalyst BioSciences.
The Catalyst stockholders will initially own approximately 65% of the combined company, with Targacept
shareholders owning the remainder.
The notes will be convertible into the combined company’s common stock at any time within two years
following closing at the discretion of those holding the notes. The conversion price of the notes is equal to $1.31,
which represents 130 percent of the negotiated per–share value of Targacept’s assets following the anticipated
distribution of the dividend of approximately $20 million and $37 million principal amount of the notes. The
conversion price was determined along with the valuation of Targacept’s shares during pre-closing negotiations.
The notes have implications for future investment capital for the firm and for the distribution of ownership. The
notes represent potentially a future source of cash for the new company, which will contribute from current cash